You have 9 free searches left this month | for more free features.

Condition

Metastatic Melanoma (1)

Metastatic Solid Tumors (1)

Non-Hodgkins Lymphoma (1)

Positron-Emission Tomography (1)

Overall Status

Completed (1)

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Hoffmann-La Roche (1)

ImaginAb, Inc. (1)

Nektar Therapeutics (1)

Collaborator

ImaginAb, Inc. (1)

Intervention

89zr-df-iab22m2c (3)

atezolizumab (1)

bempegaldesleukin (nktr-214) (1)

glofitamab (1)

nivolumab (1)

obinutuzumab (1)

polatuzumab vedotin (1)

tocilizumab (1)

Study Documents

Intervention Type

drug (3)

biological (1)

Funder Type

Industry (3)

Study Type

Interventional (3)

⁸⁹zr-df-iab22m2c

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Positron-Emission Tomography, Metastatic Solid Tumors Trial in United States (8?Zr-Df-IAB22M2C)

Completed

Positron-Emission Tomography
Metastatic Solid Tumors

⁸⁹Zr-Df-IAB22M2C

Birmingham, Alabama
+14 more

Nov 15, 2022

Metastatic Melanoma Trial in Duarte, Portland, Philadelphia (Bempegaldesleukin (NKTR-214), Nivolumab, 8?Zr-Df-IAB22M2C)

Withdrawn

Metastatic Melanoma

Bempegaldesleukin (NKTR-214)
+2 more

Duarte, California
+2 more

Jun 28, 2021

Non-Hodgkins Lymphoma Trial in Worldwide (Glofitamab, Atezolizumab, Obinutuzumab)

Recruiting

Non-Hodgkins Lymphoma

Glofitamab
+5 more

Charlotte, North Carolina
+21 more

Jan 18, 2023